Deciphera Pharmaceuticals LLC

186 articles with Deciphera Pharmaceuticals LLC

• Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results

  5/4/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update.

• Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022

  5/2/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022.

• Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

  4/29/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,501,239 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 9,748,761 shares of its common stock at an exercise price of $0.01 per share.

• Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants - Apr 27, 2022

  4/27/2022

  Deciphera Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 5,251,239 shares of its common stock at a public offering price of $10.00 per share.

• Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

  4/26/2022

  Deciphera Pharmaceuticals, Inc. announced that it intends to offer and sell $150,000,000 of shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering.

• Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting

  4/12/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of preclinical data for DCC-3116, the Company’s first-in-class ULK kinase inhibitor, in combination with KRASG12C inhibitors in non-small cell lung cancer (NSCLC) models at the American Association for Cancer Research (AACR) Annual Meeting 2022.

• Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference - Mar 09, 2022

  3/9/2022

  Deciphera Pharmaceuticals, Inc. announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami.

• Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

  2/8/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

• Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences - Feb 02, 2022

  2/2/2022

  Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences.

• Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022

  2/1/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022.

• Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

  1/24/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of results from the INTRIGUE Phase 3 study of QINLOCK (ripretinib) in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib at the American Society of Clinical Oncology (ASCO) Plenary Series Session.

• Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones

  1/10/2022

  Deciphera Pharmaceuticals, Inc. today provided a corporate update and highlighted key 2022 milestones.

• Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/3/2022

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 9:00 AM ET.

• Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations

  11/30/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), today announced a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company’s cash runway.

• 

  Deciphera Cutting 35% of Staff Amid Company Restructure

  11/30/2021

  Deciphera Pharmaceuticals announced it is restructuring with the intention of prioritizing clinical development of specific programs and streamlining its commercial operations.

• Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

  11/22/2021

  Deciphera Receives European Commission Approval of QINLOCK ® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor.

• Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study

  11/5/2021

  Deciphera Pharmaceuticals, Inc. today announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib.

• Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results

  11/2/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021

  10/26/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021.

• Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

  10/12/2021

  Deciphera Announces Approval of QINLOCK ® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor